Dr. Davids on Investigational Doublets and Triplets in CLL

Video

In Partnership With:

Matthew S. Davids, MD, MMSc, discusses investigational doublets and triplets in chronic lymphocytic leukemia.

Matthew S. Davids, MD, MMSc, director of clinical research in the Lymphoma Program and a medical oncologist with Dana-Farber Cancer Institute, as well as an assistant professor of medicine at Harvard Medical School, discusses investigational doublets and triplets in chronic lymphocytic leukemia (CLL).

The ongoing phase 2 CAPTIVATE trial is evaluating ibrutinib (Imbruvica) in combination with venetoclax (Venclexta) in patients with treatment-naïve CLL/small lymphocytic lymphoma.

According to Davids, the doublet elicits increased toxicity compared with ibrutinib or venetoclax alone; however, the efficacy of the regimen is promising.

Giving ibrutinib plus venetoclax early in the course of treatment may allow the regimen to be given as a time-limited, all-oral option, Davids says. Such an approach may be more advantageous for patients versus venetoclax plus obinutuzumab (Gazyva).

Additionally, data from The Ohio State University and a German group have demonstrated promising findings with the triplet of ibrutinib, venetoclax, and obinutuzumab (IVO) in patients with TP53-mutant CLL, says Davids.

IVO appears to be highly efficacious for patients, Davids explains. However, it does increase the risk of toxicity, including infection and infusion-related reactions.

Data with the triplet may shed light on whether adding obinutuzumab to ibrutinib/venetoclax is beneficial for patients with CLL, concludes Davids.

Related Videos
Corey Cutler, MD, MPH, and Hana Safah, MD, experts on GvHD
Shivaani Kummar, MBBS, FACP, Margaret and Lester DeArmond Endowed Chair of Cancer Research, Professor and Division Head, Division of Hematology/Medical Oncology, Oregon Health & Science University School of Medicine; co-director, Center for Experimental Therapeutics, co-deputy director, Knight Cancer Institute
Andre Goy, MD
Wenxin (Vincent) Xu, MD,
Guenther Koehne, MD, PhD
Alessandro Villa, DDS, PhD, MPH
Joseph Mikhael, MD
Michael Richardson, MD
Minesh Mehta, MD
Ruben Olivares, MD